v3.25.0.1
Summary of Significant Accounting Policies - Additional Information (Detail)
 1 Months Ended 12 Months Ended
Nov. 30, 2023
USD ($)
Aug. 31, 2024
USD ($)
shares
Dec. 31, 2024
USD ($)
ReportingUnit
$ / shares
shares
Dec. 31, 2023
USD ($)
Customer
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
$ / shares
Accounting Policies [Line Items]            
Restricted cash     $ 881,000 $ 840,000    
Allowance for doubtful accounts     1,141,000 $ 1,115,000    
Number of customers | Customer       1    
Inventory     36,900,000 $ 27,300,000    
Inventory in process     $ 1,500,000 $ 1,500,000    
Percentage of vendor payments     39.00% 33.00% 35.00%  
Due to vendor     $ 18,200,000 $ 11,800,000    
Prepaid expenses and other current assets     26,135,000 17,295,000    
Marketable equity securities     107,309,000 31,807,000    
Impairment charges related to long-lived assets     $ 0   $ 0  
Number of reporting units | ReportingUnit     1      
Goodwill impairment loss     $ 0 0 0  
Lessee, Operating Lease, Existence of Option to Extend [true false]     false      
Lessee, Operating Lease, Existence of Option to Terminate [true false]     false      
Revenue from contract with customers excluding assessed tax     $ 693,398,000 531,822,000 320,668,000  
Data and services revenue to reverse historical warrant contract asset amortization     16,300,000      
Data and services revenue to reverse historical warrant contract asset amortization, contra revenue in prior periods     11,500,000      
Warrant contract asset expense     37,800,000      
Contract with customer liability amount of revenue recognized that was included in the opening balance     69,500,000 43,500,000 13,800  
Liability for uncertain positions in Income Taxes     0 0    
Deferred offering costs     0 7,085,000    
Reclassification of deferred offering costs to additional paid-in capital upon initial public offering     12,347,000 0 0  
Other income gain     76,900,000      
Write down of warrant liability, net     0      
Accounts Receivable [Member]            
Accounting Policies [Line Items]            
Contract with customer receivable after allowance for credit loss current     $ 4,100,000 2,400,000    
Customer [Member]            
Accounting Policies [Line Items]            
Accounts receivable       $ 11,200,000    
Customer [Member] | Customer Concentration Risk [Member] | Accounts Receivable [Member]            
Accounting Policies [Line Items]            
Concentration risk, percentage       11.90%    
Equipment [Member]            
Accounting Policies [Line Items]            
Property and equipment, useful life     3 years      
Furniture and Fixtures [Member]            
Accounting Policies [Line Items]            
Property and equipment, useful life     7 years      
Minimum [Member]            
Accounting Policies [Line Items]            
Intangibles, amortization period     5 years      
Maximum [Member]            
Accounting Policies [Line Items]            
Intangibles, amortization period     7 years      
Genomics Product [Member]            
Accounting Policies [Line Items]            
Revenue from contract with customers excluding assessed tax     $ 451,700,000 $ 363,000,000 198,000,000  
Amount recognized from cash collections in excess of prior year revenues       12,200,000    
Insights Product [Member]            
Accounting Policies [Line Items]            
Revenue from contract with customers excluding assessed tax     186,800,000 117,600,000 88,400,000  
Trials Product [Member]            
Accounting Policies [Line Items]            
Revenue from contract with customers excluding assessed tax     42,400,000 45,600,000 31,200,000  
Data and Services [Member]            
Accounting Policies [Line Items]            
Revenue from contract with customers excluding assessed tax     241,649,000 168,800,000 122,684,000  
Third-Party Payor [Member] | Clinical Order [Member]            
Accounting Policies [Line Items]            
Revenue from contract with customers excluding assessed tax     409,400,000 328,400,000 157,200,000  
Self-Pay [Member] | Genomics Product [Member]            
Accounting Policies [Line Items]            
Revenue from contract with customers excluding assessed tax     42,300,000 34,600,000 $ 40,800,000  
Long-Term Contract with Customer [Member]            
Accounting Policies [Line Items]            
Revenue, remaining performance obligation     $ 202,800,000      
One Year [Member] | Long-Term Contract with Customer [Member]            
Accounting Policies [Line Items]            
Revenue, remaining performance obligation, percentage     49.00%      
Two Year [Member] | Long-Term Contract with Customer [Member]            
Accounting Policies [Line Items]            
Revenue, remaining performance obligation, percentage     36.00%      
Three Year [Member] | Long-Term Contract with Customer [Member]            
Accounting Policies [Line Items]            
Revenue, remaining performance obligation, percentage     15.00%      
Commercialization And Reference Laboratory Agreement Member With Personalis Inc [Member]            
Accounting Policies [Line Items]            
Term of agreement 3 years          
Commercialization And Reference Laboratory Agreement Member With Personalis Inc [Member] | Personalis Inc [Member]            
Accounting Policies [Line Items]            
Aggregate milestone amount payable $ 12,000,000          
Cumulative amount paid     $ 9,000,000      
Contract with customer assets net current     $ 3,000,000 $ 100,000    
Commercialization And Reference Laboratory Agreement [Member] | Prior December 31 2024 [Member] | Maximum [Member]            
Accounting Policies [Line Items]            
Class Of Warrant Share Issued | shares     4,609,400      
Commercialization And Reference Laboratory Agreement [Member] | Personalis Inc [Member]            
Accounting Policies [Line Items]            
Class Of Warrant Share Issued | shares   9,218,800 9,218,800      
Common stock purchase price   $ 18,400,000        
Commercialization And Reference Laboratory Agreement [Member] | Personalis Inc [Member] | Prior December 31 2024 [Member]            
Accounting Policies [Line Items]            
Class of warrants or rights exercise price | $ / shares     $ 1.5      
Commercialization And Reference Laboratory Agreement [Member] | Personalis Inc [Member] | Prior December 31 2025 [Member]            
Accounting Policies [Line Items]            
Class of warrants or rights exercise price | $ / shares     $ 2.5      
Commercialization And Reference Laboratory Agreement [Member] | Personalis Inc [Member] | Prior December 31 2025 [Member] | Maximum [Member]            
Accounting Policies [Line Items]            
Class Of Warrant Excisable At Cash | shares     4,609,400      
Common Class A [Member] | Master Services Agreement With Astra Zeneca As Amended [Member]            
Accounting Policies [Line Items]            
Class of warrants value of shares covered by warrants or rights           $ 100,000,000
Class of warrants or rights exercise price | $ / shares           $ 37
Federal [Member]            
Accounting Policies [Line Items]            
Net operating loss carryforwards     $ 257,000,000      
State [Member]            
Accounting Policies [Line Items]            
Net operating loss carryforwards     $ 51,700,000